Literature DB >> 23153898

Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users.

Alison B Edelman1, Ganesh Cherala, Myrna Y Munar, Barent Dubois, Martha McInnis, Frank Z Stanczyk, Jeffrey T Jensen.   

Abstract

BACKGROUND: Pharmacokinetic (PK) parameters based on short sampling times (48 h or less) may contain inaccuracies due to their dependency on extrapolated values. This study was designed to measure PK parameters with greater accuracy in obese users of a low-dose oral contraceptive (OC) and to correlate drug levels with assessments of end-organ activity. STUDY
DESIGN: Obese [body mass index (BMI) ≥30 kg/m2], ovulatory, otherwise healthy women (n=32) received an OC containing 20 mcg ethinyl estradiol (EE)/100 mcg levonorgestrel (LNG) for two cycles. EE and LNG PK parameters were characterized for 168 h at the end of Cycle 1. During cycle 2, biweekly outpatient visits were performed to assess cervical mucus, monitor ovarian activity with transvaginal ultrasound and obtain serum samples to measure EE, LNG, estradiol and progesterone levels. PK parameters were calculated and correlated with end-organ activity and compared against control samples obtained from normal and obese women sampled up to 48 h in a previous study. Standard determination of PK accuracy was performed, defined by the dependency on extrapolated values ('excess' area under the curve of 25% or less).
RESULTS: The mean BMI was 39.4 kg/m2 (SD 6.6) with a range of 30-64 kg/m2. Key LNG PK parameters were as follows: clearance, 0.52 L/h (SD 0.24); half-life, 65 h (SD 40); area under the curve (AUC), 232 h*ng/mL (SD 102); and time to reach steady state, 13.6 days (SD 8.4). The majority of subjects had increased ovarian activity with diameter of follicles ≥8 mm (n=25), but only seven women had follicles ≥10 mm plus cervical mucus scores ≥5. Evidence of poor end-organ suppression did not correlate with the severity of the alterations in PK. As compared to historical normal and obese controls (48-h PK sampling), clearance, half-life, AUC and time to reach steady state were found to be significantly different (p≤.05) in obese women undergoing a longer duration of PK sampling (168 h). Longer sampling also improved PK accuracy for obese women (excess AUC 20%) as compared to both normal and obese controls undergoing shorter sampling times (48 h) with excess AUCs of 25% and 50%, respectively.
CONCLUSIONS: Obesity results in significant alterations in OC steroid PK parameters, but the severity of these alterations did not correlate with end-organ suppression. A longer PK sampling interval (168 h vs. 48 h) improved the accuracy of PK testing.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23153898      PMCID: PMC3925642          DOI: 10.1016/j.contraception.2012.10.008

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  10 in total

Review 1.  Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles.

Authors:  D P Nicolau
Journal:  Infection       Date:  2001-12       Impact factor: 3.553

2.  Radioimmunoassay of serum d-norgestrel in women following oral and intravaginal administration.

Authors:  F Z Stanczyk; M Hiroi; U Goebelsmann; P F Brenner; M E Lumkin; D R Mishell
Journal:  Contraception       Date:  1975-09       Impact factor: 3.375

3.  Predictors of noncompliance in an oral contraceptive clinical trial.

Authors:  Carolyn L Westhoff; Anupama T Torgal; Elizabeth R Mayeda; Noa'a Shimoni; Frank Z Stanczyk; Malcolm C Pike
Journal:  Contraception       Date:  2011-11-12       Impact factor: 3.375

Review 4.  Pharmacokinetics of gestagens: some problems.

Authors:  K Fotherby
Journal:  Am J Obstet Gynecol       Date:  1990-07       Impact factor: 8.661

Review 5.  Obesity and reproduction: an educational bulletin.

Authors: 
Journal:  Fertil Steril       Date:  2008-11       Impact factor: 7.329

6.  Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women.

Authors:  Carolyn L Westhoff; Anupama H Torgal; Elizabeth R Mayeda; Malcolm C Pike; Frank Z Stanczyk
Journal:  Contraception       Date:  2010-02-20       Impact factor: 3.375

7.  Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel.

Authors:  Anna Glasier; Sharon T Cameron; Diana Blithe; Bruno Scherrer; Henri Mathe; Delphine Levy; Erin Gainer; Andre Ulmann
Journal:  Contraception       Date:  2011-04-02       Impact factor: 3.375

8.  Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial.

Authors:  Carolyn L Westhoff; Anupama H Torgal; Elizabeth R Mayeda; Frank Z Stanczyk; Jodi P Lerner; Emma K T Benn; Myunghee Paik
Journal:  Obstet Gynecol       Date:  2010-08       Impact factor: 7.661

9.  Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity.

Authors:  Alison B Edelman; Nichole E Carlson; Ganesh Cherala; Myrna Y Munar; Richard L Stouffer; Judy L Cameron; Frank Z Stanczyk; Jeffrey T Jensen
Journal:  Contraception       Date:  2009-06-04       Impact factor: 3.375

10.  Contraceptive considerations in obese women: release date 1 September 2009, SFP Guideline 20091.

Authors:  Susan Higginbotham
Journal:  Contraception       Date:  2009-09-24       Impact factor: 3.375

  10 in total
  16 in total

Review 1.  Obesity and contraception.

Authors:  Sheila K Mody; Michelle Han
Journal:  Clin Obstet Gynecol       Date:  2014-09       Impact factor: 2.190

2.  Levonorgestrel butanoate intramuscular injection does not reliably suppress ovulation for 90 days in obese and normal-BMI women: a pilot study.

Authors:  Alison B Edelman; Ganesh Cherala; Hong Li; Francis Pau; Diana L Blithe; Jeffrey T Jensen
Journal:  Contraception       Date:  2016-07-27       Impact factor: 3.375

3.  Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women.

Authors:  Teresa Barcellos; Melissa Natavio; Frank Z Stanczyk; Dandan Luo; William J Jusko; Nicole M Bender
Journal:  Contraception       Date:  2019-06-10       Impact factor: 3.375

4.  Effectiveness of progestin-based therapy for morbidly obese women with complex atypical hyperplasia.

Authors:  Marcia A Ciccone; Stephanie A Whitman; Charlotte L Conturie; Niquelle Brown; Christina E Dancz; Begum Özel; Koji Matsuo
Journal:  Arch Gynecol Obstet       Date:  2019-01-31       Impact factor: 2.344

5.  An ethinyl estradiol-levonorgestrel containing oral contraceptive does not alter cytochrome P4502C9 in vivo activity.

Authors:  Ganesh Cherala; Jacob Pearson; Cheryl Maslen; Alison Edelman
Journal:  Drug Metab Dispos       Date:  2013-12-24       Impact factor: 3.922

Review 6.  Clarification of contraceptive drug pharmacokinetics in obesity.

Authors:  William J Jusko
Journal:  Contraception       Date:  2016-08-16       Impact factor: 3.375

7.  Altered pharmacokinetics of combined oral contraceptives in obesity - multistudy assessment.

Authors:  Dandan Luo; Carolyn L Westhoff; Alison B Edelman; Melissa Natavio; Frank Z Stanczyk; William J Jusko
Journal:  Contraception       Date:  2019-01-23       Impact factor: 3.375

8.  Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy.

Authors:  Barent N DuBois; Jessica Atrio; Frank Z Stanczyk; Ganesh Cherala
Journal:  Contraception       Date:  2014-08-30       Impact factor: 3.375

9.  Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing.

Authors:  Alison B Edelman; Ganesh Cherala; Steven W Blue; David W Erikson; Jeffrey T Jensen
Journal:  Contraception       Date:  2016-03-18       Impact factor: 3.375

10.  Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial.

Authors:  Alison B Edelman; Ganesh Cherala; Myrna Y Munar; Martha McInnis; Frank Z Stanczyk; Jeffrey T Jensen
Journal:  Contraception       Date:  2014-06-27       Impact factor: 3.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.